Prognostic Analysis of PTEN Mutation in Endometrial Carcinoma

Abstract

Purpose: Endometrial carcinoma (EC) is recognized as one of the most common female reproductive system malignant tumors. Great efforts have been made to improve the diagnosis and prognostic analysis of EC, however, more sensitive prognostic evaluation system for EC remains to be established. The mutation status of PTEN and its association with clinical characteristics, as well as its prognostic value in EC need to be evaluated.Methods: TCGA dataset comprised of 526 EC cases were used to perform a comprehensive analysis of PTEN mutation. Kaplan‐Meier survival plot were performed to analyze the clinical significance of PTEN mutation. GO, KEGG pathway and IPA network analysis were performed to identify the specific pathways for PTEN mutation patients. And the prognostic value of PTEN mutation was further analyzed.Results: Here, the highest mutation frequency of PTEN (65%) was found in EC from Pan cancer. PTEN mutation status was significantly correlated with the better prognosis of EC patients. A total of 66 differentially expressed genes (DEGs) were identified between PTEN-mutant and PTEN-wild groups. KEGG pathway enrichment analysis suggested that some key pathways were relevant to the tumorigenesis and development of EC. The DEGs were mainly associated with endocrine and reproduction related pathways based on the IPA analysis. Then, a PTEN related-genes prognostic signature including CLDN9, UCHL1, BEX2, SLC47A1, PGR, SLC25A35, SCGB2A1, MSX1, CRABP2 and MAL was established. The K-M result showed the significant differences of survival rate between high- and low- risk groups. Furthermore, univariate and multivariate Cox regression analysis results indicated that age, figo_stage and risk score could be identified as independent prognostic factors. Finally, a nomogram for predicting survival rate was established.Conclusion: The above data suggested that PTEN mutation status could be serviced as a potential prognostic biomarker for EC, which might guide future EC personalized treatment.